Zacks Investment Research on MSN4d
AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis StudyAmgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) ...
Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...
New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...
Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...
Clinical Trials Arena on MSN7d
Amgen’s gMG therapy cuts disease symptoms at one-year markAmgen’s Uplizna (inebilizumab-cdon) has shown sustained efficacy in a group of gMG patients after 52 weeks in a Phase III ...
With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...
Amgen has shared new data from a late-stage trial of its B cell-depleting therapy Uplizna (inebilizumab-cdon) in adults with the rare autoimmune disorder generalised myasthenia gravis (gMG). The phase ...
Shares of Zenas BioPharma (NASDAQ:ZBIO) rose on Thursday after Wedbush launched the newly IPO’ed biotech's coverage with an ...
Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s ...
Amgen has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating generalized myasthenia gravis, likely influencing its 14% price increase over the last ...
Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) for label expansion in generalized myasthenia gravis (gMG) indication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback